Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SL-172154 Monotherapy in Ovarian Cancer
NCT04406623Phase 1Completed
- Sponsor
- Shattuck Labs
- Start
- Jun 2020
- Primary completion
- Feb 2023
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of SL-172154 in ovarian cancer, fallopian tube cancer (PFTC) and primary peritoneal carcinoma (PPC), sponsored by Shattuck Labs. Primary endpoints: Safety Profile of SL-172154 and Maximum Tolerated Dose. Started Jun 2020; status: completed.
02
Drugs
SL-172154
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal carcinoma (PPC)
Beyond the preview
Go deeper on NCT04406623.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04406623.